Skip to Content

Generic Copiktra Availability

Last updated on Sep 8, 2021.

Copiktra is a brand name of duvelisib, approved by the FDA in the following formulation(s):

COPIKTRA (duvelisib - capsule;oral)

  • Manufacturer: SECURA
    Approval date: September 24, 2018
    Strength(s): 15MG [RLD], 25MG [RLD]

Has a generic version of Copiktra been approved?

No. There is currently no therapeutically equivalent version of Copiktra available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Copiktra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Substituted isoquinolin-1(2H)-ones, and methods of use thereof
    Patent 8,193,182
    Issued: June 5, 2012
    Inventor(s): Ren; Pingda & Liu; Yi & Wilson; Troy Edward & Li; Liansheng & Chan; Katrina & Rommel; Christian
    Assignee(s): Intellikine, Inc.

    Chemical entities of Formula I: that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.

    Patent expiration dates:

    • February 13, 2030
      ✓ 
      Drug substance
  • Certain chemical entities, compositions and methods
    Patent 9,216,982
    Issued: December 22, 2015
    Assignee(s): Intellikine LLC

    Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.

    Patent expiration dates:

    • January 5, 2029
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)
    • January 5, 2029
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)
  • Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
    Patent 9,840,505
    Issued: December 12, 2017
    Assignee(s): Infinity Pharmaceuticals, Inc.

    Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.

    Patent expiration dates:

    • January 10, 2032
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)
    • January 10, 2032
      ✓ 
      Patent use: FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)
  • Processes for preparing isoquinolinones and solid forms of isoquinolinones
    Patent RE46621
    Issued: December 5, 2017
    Assignee(s): Infinity Pharmaceuticals, Inc.

    Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.

    Patent expiration dates:

    • May 17, 2032
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • September 24, 2023 - NEW CHEMICAL ENTITY
    • September 24, 2025 -
    • September 24, 2025 -

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.